TGFB1 and non-small cell lung carcinoma: To increase the anti-cancer efficacy of gefitinib and reduce side effects, we evaluated the combinatorial effect of peptide drug cilengitide with gefitinib on cell survival and TGF-β-mediated EMT in NSCLC cells.